New Treatment Options in ER-Positive, HER2-Positive and Triple-Negative Breast CancerDiagnostic criteriaPathologyWHO classificationBreast CancerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, ...
EP: 12.Treatment Options for HER2+, ER+ Metastatic Breast Cancer EP: 13.Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer Vijayakrishna Gadi, MD, PhD: I’m going to go with that a little further. So Nancy, when you think about hormone-positive, HER2-positive disease, so maybe...
HER2-directed therapy: current treatment options for HER2-positive breast cancer Over the past decade, the management of HER2-positive breast cancer has evolved dramatically. In addition to advances in screening, genetic testing, imagin... S Ahmed,A Sami,J Xiang - 《Breast Cancer》 被引量: 74...
[2]Miglietta F, Bottosso M, Griguolo G, et al. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open. 2022;7(2):100409. [3]Agostinetto E, Curigliano G, Piccart M. Emerging treatments in HER2-positive advanced breast cancer:...
[2]Miglietta F, Bottosso M, Griguolo G, et al. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open. 2022;7(2):100409. [3]Agostinetto E, Curigliano G, Piccart M. Emerging...
A video from Virginia Borges (as part of University of Colorado Cancer Center), posted on Apr 14, 2023.
在中国,乳腺癌已成为女性恶性肿瘤中的头号杀手,而超过 90% 的女性在首次诊断时处于疾病早期 [1] 。在早期乳腺癌患者中,HR+/HER2-型占据了绝大多数。在早期 HR+/HER2-乳腺癌的治疗中,辅助内分泌治疗已经显著改善了患者的预后,并提高了他们的生存率。尽管取得了这样的进展,大约 20% 至 30% 的早期乳腺癌患者...
Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer. Sara A. Hurvitz, MD The year 2020 saw a myriad of promising studies that resulted in several FDA-approved options for patients wit...
[1] Ma J, Chan JJ, Toh CH, Yap YS. Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer. 2023 Sep 8;9(1):74. [2] Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistan...
"The priority review designation for zanidatamab underscores the critical need for new treatment options for patients with locally advanced or metastatic HER2-positive BTC, a devastating disease with a poor prognosis," saidRob Iannone, M.D., M.S.C.E., executive vice p...